account_name,fit,urgency,total,fit_reason,urgency_reason,urgency_source,trigger_summary,sec_matched_total,sec_examples,patent_matched_total,patent_examples,job_target_roles
AstraZeneca,1.0,0.0,4.0,no trials,no trials and no relevant sec/patent signals,none,sec_filing: 6-K filed 2026-02-10 – FINAL RESULTS | sec_filing: 6-K filed 2026-02-02 – IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | sec_filing: 6-K filed 2026-01-29 – ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030,0,[],0,[],"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
GSK,1.0,0.0,4.0,no trials,no trials and no relevant sec/patent signals,none,,0,[],0,[],"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
Pfizer,1.0,0.0,4.0,no trials,no trials and no relevant sec/patent signals,none,,0,[],0,[],"[""Director/VP, Translational Medicine (Oncology/Immunology)"", ""Head/Director, Clinical Biomarkers / Translational Biomarkers"", ""Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core"", ""Director, Bioassay / Potency / Analytical Development"", ""Clinical Scientist / Early Clinical Development Lead (Phase 1)""]"
